Format

Send to

Choose Destination
J Pharm Sci. 2018 Aug;107(8):2020-2032. doi: 10.1016/j.xphs.2018.03.030. Epub 2018 Apr 14.

A Refined Developability Classification System.

Author information

1
Institute of Pharmaceutical Technology, Goethe University, Frankfurt/Main, Germany.
2
Pharmaceutical Development and Supply, GlaxoSmithKline R&D, Ware, UK.
3
Institute of Pharmaceutical Technology, Goethe University, Frankfurt/Main, Germany. Electronic address: dressman@em.uni-frankfurt.de.

Abstract

In 2010, the Developability Classification System (DCS) was proposed. The DCS was designed to close the gap between the biopharmaceutics classification system, which is aimed at guiding regulatory decisions about well-characterized drugs, and the need for early evaluation of drug candidates with respect to their suitability for oral delivery. The DCS applied solubility in fasted state simulated intestinal fluid to estimate intestinal solubility, assessed the compensatory nature of permeability and solubility during oral absorption and provided a way of estimating the critical the particle size at which dissolution becomes rate-limiting to absorption. Building on this framework, a refined developability classification system (rDCS) is now proposed. The rDCS is stratified into standard investigations applied to all candidates, and customized investigations. Standard investigation of solubility and permeability can be performed according to in-house methods, and the results compared with standard data sets of fasted state human intestinal fluid solubility and human effective jejunal permeability, which have been generated specifically for rDCS. Customized investigations are triggered when there is potential for supersaturation/precipitation (weak bases; salts of weak acids) and to assess dissolution versus permeation limited absorption. In addition, the rDCS offers facile visualization of the results, enabling pragmatic comparison of drug candidates and formulation approaches.

KEYWORDS:

Biopharmaceutics Classification System (BCS); dissolution; formulation; high throughput technology(s); in vitro model(s); oral absorption; permeation enhancers(s); solubility; supersaturation

PMID:
29665381
DOI:
10.1016/j.xphs.2018.03.030

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center